An Indian drugmaker has halted production of a couple of APIs for the U.S. after FDA inspectors found it was falsifying data at its manufacturing complex near Tamil Nadu, India. That was just the beginning of the problems.Original Article
FDA warning thrashes Indian drugmaker for filthy plant, data falsification
